March 9 marks the devastating anniversary of the day my stepson Max died after a three-year battle with cancer. Max was 17 years old. I have dedicated most of the last 34 years to galvanizing the global community to help families avoid the suffering of the premature loss of their loved one. In the process, a thriving global network of people helping people emerged as a beacon of hope and light. The work we do at The Max Foundation elevates the common humanity and interconnectedness among all of us, no matter where we live. We are one, we long for the same, we need each other.
This year, March 9 finds us navigating difficult times yet unwilling to accept a global current that wants to convince us to focus on ourselves and ignore those most vulnerable among us.
While trying to find my footing, a news article published recently resonated with me and reminded me that our capacity to act with humanity is still intact. Today my feelings can be summarized in one short message: this is not the time to be a goldfish. I invite you to read my editorial, published in Devex, and share widely.
Pat Garcia-Gonzalez is the CEO of The Max Foundation. Under Pat’s direction The Max Foundation is dedicated to accelerating health equity by delivering medication, technology, and services to patients facing cancer and other critical illnesses, focusing our energy on those who no one else is helping. Pat lives in Edmonds, Washington, where she raised her four sons.
Earlier this month, The Max Foundation celebrated the delivery of 110 BCR-ABL molecular tests to Mercy Medical Center Cambodia. The delivery was the first of its kind for Max, made possible through our 2018 Diagnostics Solidarity Fund. Two more deliveries – one to Kyrgyzstan and one to Bolivia – are in process now, and we’re hopeful there will be many more to come.
SEATTLE, Washington – May 17, 2023 – The Max Foundation (Max), a global nonprofit organization dedicated to accelerating health equity by delivering medication, technology, and supportive services to patients worldwide, BeiGene, a global biotechnology company, and the BeiGene Foundation, a nonprofit charitable foundation, today announced a collaboration to provide access to BRUKINSA (zanubrutinib) for the….
Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.
